Lonza to make drug active for Aurinia

Department: Business
Keywords: pharmaceutical chemicals, voclosporin, lupus nephritis, Lonza

Business Concentrates

Petrobras sells business at a bargain price
Air Products, Huntsman complete sales
DuPont settles mercury suit
Covestro funds catalyst R&D center
Sumitomo, Purdue target plant analysis
Air Liquide exits diving equipment
Synthego raises funds from big names
Lonza to make drug active for Aurinia
A flurry of deals signed by J&J
Chinese firm hampers FDA inspection
Lilly, Bayer help animal health deal
Life science fund gets interdisciplinary
Business Roundup
All Concentrates

Lonza has signed an agreement to manufacture voclosporin for use by the biotech firm Aurinia in a Phase III clinical trial of the drug as a lupus nephritis treatment. Lonza has an option to supply the compound for up to 20 years. Aurinia CEO Charles Rowland says his firm spent years working with Lonza to optimize the drug’s complex manufacturing process.

Topics

MAGAZINE

COLLECTIONS

VIDEOS

JOBS